BeOne Medicines (HKSE:06160) Cash Receipts from Deposits by Banks and Customers

View and export this data going back to 2018. Start your Free Trial

What is BeOne Medicines Cash Receipts from Deposits by Banks and Customers?

Cash Receipts from Deposits by Banks and Customers only applicable to companies reporting Cash Flow from Operations in direct method.

BeOne Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (HKSE:06160) » Definitions » Cash Receipts from Deposits by Banks and Customers

Comparable Companies

Traded in Other Exchanges

BEIGF:USA ONC:USA 49B:Germany 688235:China B1ME34:Brazil

Address

c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel, CHE, 4051

Website

https://www.beonemedicines.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

Executives

Baker Felix James	2201 Interest of corporation controlled by you
Baker Julian Charles	2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc	2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2502 Approved lending agent
Oyler John Victor	2101 Beneficial owner
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd.	2102 Investment manager
Hhlr Fund, L.p.	2101 Beneficial owner
Amgen Inc.	2101 Beneficial owner
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.